Codexis reported fourth-quarter 2025 revenue of $38.9 million and full-year revenue of $70.4 million, buoyed by a $37.8 million technology transfer with Merck. The company ended the year with $78.2 million in cash and short-term investments, guided 2026 revenue to $72–76 million, and expects its runway to extend through 2027. Product gross margin improved to 64% for the year, and Codexis posted a profitable Q4 while narrowing its full-year net loss. Operationally, the company advanced its Eco Synthesis enzymatic manufacturing platform for RNAi therapeutics, progressed more than 50 active opportunities with innovators and CDMOs, signed a GMP facility lease targeting full production by the end of 2027, and prepared for the commercial launch of two pharma biocatalysis products following positive phase 3 data.

The strategic subtext is clear: a tools player is inching toward the CDMO lane. By pairing enzyme IP with GMP footprint, regulatory engagement, and CDMO collaborations, Codexis is positioning to capture more value in an oligonucleotide market where manufacturing is increasingly a differentiator. The Q4 revenue spike highlights non-recurring tech transfer economics, but the groundwork suggests a bid for repeatable, program-linked revenue as partners move into IND-enabling and clinical supply. The near-term test is whether feasibility pilots convert into clinical-stage manufacturing agreements and platform licenses at the pace implied by the pipeline of 55 prospects.

This matters because the economics and reliability of RNAi supply are now central to clinical development and market access. Eco Synthesis aims to solve persistent pain points of chemical phosphoramidite routes—low stepwise yields, PS stereochemical heterogeneity, solvent-intensive waste, and scale constraints. Codexis demonstrated a fully enzymatic 10 g siRNA batch and a 3 kg customer batch using its ligase, signaling movement toward commercial volumes. If stereochemistry control translates into higher potency and cleaner safety profiles, developers could lower doses, streamline formulations, and potentially improve payer narratives on cost per outcome. For patients and HCPs, more predictable supply and improved product attributes could ease adoption as RNAi diversifies into metabolic, cardiology, and hepatic indications.

Regulatory posture will be pivotal. Ongoing engagement with the FDA’s Emerging Technologies team on product quality, stereochemical control, and comparability underscores the industry-wide question: can sponsors switch to enzymatic processes mid-development without incurring prohibitive bridging burdens? Medical Affairs teams should anticipate expanded evidence plans to support equivalence and real-world performance if manufacturing transitions occur between phases or pre-launch. The ISO 9001 certification and successful partner audit de-risk basic quality expectations, but broad acceptance hinges on transparent CMC packages and cross-referenced analytics that regulators and payers can trust.

Commercially, the company’s CDMO outreach—now including Axolabs—reflects a pragmatic channel strategy as established oligo manufacturers scale capacity and large pharmas secure supply via tech transfers and long-dated contracts. The targeted 2026 strategic CDMO partnership and a potential big pharma license in the second half of 2026 are critical catalysts that would validate platform stickiness beyond one-off deals. Meanwhile, two biocatalysis products nearing commercial launch could add steadier product revenue to complement milestone-heavy collaboration income.

The broader trend is an arms race to industrialize next-generation oligonucleotide manufacturing with greener processes, tighter quality attributes, and lower COGS. The next 12 to 18 months will reveal whether enzymatic synthesis moves from compelling demos to a preferred standard. Watch for clinical-stage manufacturing conversions from Codexis’s prospect pool, data on stereospecific benefits at TIDES and beyond, and tangible progress on the GMP facility. If those pieces align, the competitive question becomes whether entrenched chemical platforms adapt fast enough—or whether enzymatic routes become the default for scalable, payer-friendly RNAi.

Source link: https://www.globenewswire.com/news-release/2026/03/11/3254133/0/en/Codexis-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.